For any media enquiries,
Please contact: info@stabilitech.com
PRESS RELEASE
iosBio takes next step in race for a vaccine, announces BioCell as manufacturer for OraPro-COVID-19
Burgess Hill, UK, 12 June 2020 STABILITECH BIOPHARMA LTD (“iosBio”), a UK biotechnology company developing next generation vaccines and biopharmaceuticals, has announced today a partnership with BioCell Corporation (New Zealand) to manufacture its oral coronavirus vaccine, OraPro-COVID-19. Read more
Downloadable media assets
| Press release doc | ||
|---|---|---|
 |
 |
PRESS RELEASE
iosBio Biopharma earns prestigious position on WHO list of vaccine developers
Burgess Hill, UK, 11 May 2020 STABILITECH BIOPHARMA LTD (“iosBio”), a UK biotechnology company developing next generation vaccines and biopharmaceuticals, announces today that, they have been recognised on a global level by the World Health Organisation (WHO) as a vaccine developer. Read more
Downloadable media assets
| Press release doc | ||
|---|---|---|
|
|
PRESS RELEASE
iosBio Biopharma strengthens leadership team, as Jeffrey Almond joins the board in race to develop oral vaccine for COVID-19
Burgess Hill, UK, 07 May 2020 STABILITECH BIOPHARMA LTD (“iosBio”), a UK biotechnology company developing next generation vaccines and biopharmaceuticals, has today announced that Professor Jeffrey Almond will be joining the board as they step up their efforts in search of a vaccine for COVID-19. Read more
Downloadable media assets
| Press release doc | ||
|---|---|---|
|
|
PRESS RELEASE
iosBio Biopharma joins race to develop COVID-19 vaccine delivering unique double immunity using self-administered capsules
Burgess Hill, UK, 30 April 2020 STABILITECH BIOPHARMA LTD (“iosBio”), a UK biotechnology company developing next generation vaccines and biopharmaceuticals, has announced today that, it is seeking an investment of £6m to fund clinical trials and manufacturing of an oral coronavirus vaccine, OraPro-COVID-19. Read more
Downloadable media assets
| Press release doc | Full Zip Download | |
|---|---|---|
|
 |
|
iosBio in the media
Kyiv Post
TRT World
Newsmax
Could an Old Polio Vaccine Conquer the Current Coronavirus? -12/06/2020
BioSpace
Biopharma Update on the Novel Coronavirus: June 12 – 12/06/2020
France 24
Vox
Why a vaccine may not be enough to end the pandemic – 03/06/2020
The Washington Post
The FDA should not rush a covid-19 vaccine – 02/06/2020
La Nación
Científicos argentinos desarrollarán vacuna contra el coronavirus – 01/06/2020
Extra Globo
Cientistas buscam locais críticos da pandemia em corrida para testar vacinas contra a Covid-19 – 01/06/2020
APA Science
London will Führung bei Corona-Impfstoff übernehmen – 01/06/2020
Executive Digest
Vacinas contra o novo coronavírus? Estas são as 10 principais candidatas – 28/05/2020
The Wall Street Journal
‘Vaccine Nationalism’: A New Dynamic in the Race to Quash Coronavirus – 27/05/2020
STAT
Beating Covid-19 will change how new therapies are developed – 27/05/2020
The Daily Express
Over-55s will get new vaccine as army of 10,000 is recruited – 23/05/2020
France 24
Virus-stung UK banks on vaccine drive – 22/05/2020
ITV
Tonight – The Race for a Cure: Making Britain Safe – 21/05/2020
Genetic Engineering & Biotechnology News
COVID-19 candidates: iosBio Biopharma – 19/05/2020
The Daily Telegraph
Britain in coronavirus lockdown, in pictures – 19/05/2020
Business Insider Italia
Viene dall’Inghilterra la speranza di un vaccino in pillola: “Sarà come prendere un’aspirina” – 17/05/2020
OnDrugDelivery
iosBio recognised by WHO, seeks £6m to make oral SARS-COV-2 vaccine available by end of 2020 – 12/05/2020
Pharmaceutical-Technology.com
WHO recognises UK’s iosBio as a Covid-19 vaccine developer – 12/05/2020
The Biologist
Why an oral vaccine could be key to fighting COVID-19 – 09/05/2020
Biotech Capital
iosBio Biopharma working on a breakthrough coronavirus vaccine that can be taken in pill form – 07/05/2020
Proactive Investors
iosBio Biopharma to takes its ‘revolutionary’ COVID-19 vaccine capsule into the clinic – 04/05/2020
Los Angeles Times
Too many ‘shiny objects’: Why it’s risky to promise a coronavirus vaccine and cure – 01/05/2020
Biospace.com
Biopharma update on the Novel Coronavirus: April 30 – 30/04/2020
The Pharma Letter
iosBio joins COVID-19 vaccine race, but needs funding – 30/04/2020
BioWorld
Other news to note for April 30, 2020 – 30/04/2020
CNBC NEWS – USA
UK biotech developing oral COVID-19 vaccine that could be delivered in the mail – 6/04/2020
FirstWorld PHARMA
iosBio’s COVID-19 Vaccine Intended to Be Delivered in a Disruptive Thermally Stable Oral Capsule – 19/03/2020
USA LIFE SCIENCES DATABASE
iosBio’s COVID-19 Vaccine Intended to Be Delivered in a Disruptive Thermally Stable Oral Capsule – 23/04/2020
EPR – EUROPEAN PHARMACEUTICAL REVIEW
Novel thermally-stable COVID-19 vaccine capsule developed – 19/03/2020
Click through each Tab below to download resources.
iosBio media FAQs
iosBio media images
Clinical Trials: An Overview
OraPro-COVID-19 Mucosal & Systemic Immunity: An Overview
COVID-19
- Millions of people infected.
- Billions of people affected.
- Trillions of dollars invested.
The world is fighting back.
iosBio is part of that fight – you can be too.
The OraPro-COVID-19. A coronavirus vaccine that delivers double immunity via a capsule that may be delivered by post that can be swallowed. No needles, no doctors or nurses, no queues for a vaccine, no risk of cross infection.
The Los Angeles Times’ Ralph Vartabedian says:
“The company has taken a harmless virus common in the human body and modified its genetic structure to include two genes that are responsible for the now famous spikes in the coronavirus. It is formulated into a pill that, when digested, would prompt the immune system to produce antibodies to attack the coronavirus spikes. The approach requires small amounts of the drug, meaning it would be easier to manufacture for universal consumption.”
Thermally stable, self-administered vaccines in capsule form are the future